Bank of America’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
TSC
MCM
Bank of America's LUCD Position: Q2 2026 in Review
Bank of America increased its Lucid Diagnostics (LUCD) stake by 9.3% in Q2 2026, buying an estimated $8.89K and bringing the position to 96,776 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #5525.
Bank of America first reported a position in LUCD in Q4 2021 and has held it in 16 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.
- Bank of America held 96,776 shares of Lucid Diagnostics worth $104K as of Q2 2026.
- Bank of America bought 8,249 Lucid Diagnostics shares in Q2 2026, an estimated $8.89K.
- Lucid Diagnostics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5525 holding.
- Bank of America first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 16 quarters since.
- 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.